Clinical trials: Aggressive Behavior
Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
This phase I trial seeks to find out the best dose, possible benefits and/or side effects of entinostat in combination with atezolizumab, carboplatin and etoposide for the treatment of previously untreated aggressive lung cancer…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT04631029
- Testing
- Atezolizumab, Carboplatin, Entinostat
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Symptomatic Non-acute Intracranial Artery Occlusion, Ischemic Stroke
Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR）
A multicenter, randomized, open-label, endpoint-blinded trial to compare the effects of endovascular recanalization plus aggressive medical management with aggressive medical management alone on stroke recurrence and mortality in…
- Trial name
- NCT07495969
- Testing
- Endovascular Recanalization Strategy, Aggressive Medical Management
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Feng Gao
Desmoid Tumors, Aggressive Fibromatosis
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
Background: Desmoid tumors (also known as aggressive fibromatosis), are rare, locally invasive, slow-growing soft-tissue tumors.
- Trial name
- NCT01981551
- Testing
- PF-03084014
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Disruptive Behavior, Aggression
Cognitive-Behavioral Therapy for Disruptive Behavior in Children and Adolescents
This is a randomized controlled study of cognitive-behavioral therapy (CBT) for disruptive behavior such as irritability, anger and aggression in children and adolescents.
- Conditions
- Disruptive Behavior, Aggression, Anger, Irritability
- Trial name
- RDoC-CBT (NCT01965184)
- Testing
- Cognitive-Behavioral Therapy for Anger and Aggression, Supportive Psychotherapy (SPT)
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Yale University
Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma
Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer
This phase II trial tests whether vudalimab works to shrink tumors in patients with anaplastic thyroid cancer or hurthle cell thyroid cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to…
- Conditions
- Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Oncocytic Carcinoma
- Trial name
- NCT05453799
- Testing
- Vudalimab
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Northwestern University
Lymphoma
Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different ways may kill more cancer cells.
- Trial name
- NCT00053768
- Testing
- filgrastim, EPOCH regimen, cyclophosphamide
- Where
- 175 sites in Germany, Switzerland
- Volunteers
- 392 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Cancer
Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors
Part 1: 16 to 32 patients with aggressive solid tumors from whom biopsies can be obtained, will receive BO-112 through IT administration.
- Trial name
- NCT02828098
- Testing
- Part 1: BO-112, Part 2: BO-112
- Where
- 7 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Highlight Therapeutics
Impulsive Aggression, ADHD
Dialectical Behavioral Therapy Skills for Impulsive Aggression
This trial aims to Study the efficacy of DBT skills for impulsive aggression and executive dysfunctions in drug naïve children who are presented with impulsive aggression and ADHD and attending Child and adolescent clinic at…
- Conditions
- Impulsive Aggression, ADHD, Executive Dysfunction
- Trial name
- NCT05351944
- Testing
- Dialectical behavioral therapy skills for the intervention experimental group A, psychoeducation or Atomoxetine or stimulants according to ADHD severity
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Alexandria University
Autism Spectrum Disorder, Developmental Disability
Propranolol for Challenging Behaviors in Autism
Severe challenging behaviors such as aggression and self-injury can cause significant morbidity and decrease the quality of life for individuals with Autism Spectrum Disorders (ASD).
- Conditions
- Autism Spectrum Disorder, Developmental Disability, Aggression, Self-Injurious Behavior
- Trial name
- NCT04047355
- Testing
- Propranolol
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Rutgers, The State University of New Jersey
Leukemia, Hodgkin Lymphoma
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
The goals of the study are (Phase I) to determine the appropriate dose for Clofarabine with Busulfan as a full-intensity conditioning (Clo/BU4 regimen) prior to transplant and then (Phase II) to investigate the safety and…
- Conditions
- Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma
- Trial name
- NCT00556452
- Testing
- Clofarabine/Busulfan x 4, Peripheral blood stem cell transplant, Total Lymphoid Irradiation
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Michigan Rogel Cancer Center
Psychological Distress, Suicidal Ideation
Flourish in Schools Pilot Study
This study will test Flourish, a digital suicide prevention intervention for cyberbullied youth, within schools. Specifically, the study aims to: 1.
- Trial name
- NCT07506525
- Testing
- Flourish
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Candice Biernesser
Pancreatitis
Randomized Trial of Aggressive Fluid Hydration to Prevent Post ERCP Pancreatitis
1. ERCP is a commonly performed endoscopic procedure used to treat stones and blockages of the bile duct as well as to manage leaks which occurs following laparoscopic gallbladder removal. 2.
- Trial name
- NCT01758549
- Testing
- Aggressive Intravenous Hydration Group, Standard Fluids Arm
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Southern California
Autism Spectrum Disorder
VGN-Ex05e in Patients With Autism Spectrum Disorder Associated With Severe Self-Injurious and Aggressive Behaviors
To evaluate the safety and tolerability of intracerebral injection of VGN-Ex05e in the nucleus accumbens of patients with autism spectrum disorder.
- Trial name
- NCT07433517
- Testing
- VGN-Ex05e
- Volunteers
- 6 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
This is a phase I, open label, single-arm, multi-center, dose-finding study of venetoclax in combination with DA-EPOCH-R in patients with aggressive B-Cell Lymphomas.
- Trial name
- V+DA-EPOCH-R (NCT03036904)
- Testing
- Venetoclax, Rituximab, Etoposide
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- Weill Medical College of Cornell University
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute
Lymphoma, B-Cell
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
The purpose of this study is to find the highest dose of a new drug, in combination with standard drugs, which can be tolerated without causing very severe side effects.
- Trial name
- NCT04161248
- Testing
- Venetoclax, Rituximab Injection, Rituximab SC
- Where
- 4 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Canadian Cancer Trials Group
SCHIZOPHRENIA 1 (Disorder)
Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients
The purpose of this study is to determine effect of Fluvoxamine augmentation on cognitive function , aggressive behavior , clinical symptoms and mRNA (messenger ribonucleic acid) and protein expression in human peripheral…
- Trial name
- NCT01832285
- Testing
- fluvoxamine
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Sha'ar Menashe Mental Health Center
Cancer
Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses
This is a prospective, open-label navigational investigation designed to evaluate the feasibility of using molecular profile-based evidence to determine individualized cancer therapy for patients with aggressive malignancies.
- Trial name
- MCW I-PREDICT (NCT05674825)
- Testing
- Targeted agent, Standard of care agent
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Medical College of Wisconsin
Mycosis Fungoides, Lymphoma, Large B-cell, Diffuse
Cell-free Circulating DNA in Primary Cutaneous Lymphomas
To evaluate the possibility of detecting cell-free circulating tumoral DNA in potentially aggressive primary cutaneous lymphomas, the investigator opted to search a representative tumor sample mutation in the blood of these…
- Trial name
- MATULILA (NCT02883517)
- Testing
- Cytogenetic and molecular studies
- Where
- France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Bordeaux